Recombinant BCG Vaccine Antigens for TB Discrimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for tuberculosis, such as the tuberculin skin test and interferon-y release assays, face challenges in distinguishing between active TB, latent TB infection, and previous TB infection, leading to false positives and unnecessary treatment due to cross-reactivity with other mycobacteria and BCG vaccination, and lack specificity in identifying active disease.
Innovation Solution
Development of immunological compositions comprising three specific Mycobacterium tuberculosis antigens (Putative cyclopropane-fatty-acyl-phospholipid synthase, Possible glycosyltransferase, and another Possible glycosyltransferase) and their encoding nucleic acids, used in recombinant BCG vaccines to enhance immune response and improve TB diagnosis and vaccination strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic tests (TST or IGRA) are used to detect TB infection, then the testing process is simple and widely accessible, but the tests cannot discriminate between active TB, latent TB infection, and previous TB infection, leading to false positives
Solution Approach 1:
The patent divides the diagnostic approach into multiple specific antigen components (Rv3874c, Rv2681c, Rv3615c) rather than using a single aggregated antigen preparation. This segmentation allows the diagnostic system to detect specific immune responses to individual antigens, improving the ability to discriminate between different TB infection states while maintaining a manageable test structure.
Solution Approach 2:
The patent employs a composite antigen formulation combining three specific M. tuberculosis antigens (Rv3874c, Rv2681c, Rv3615c) in defined proportions. This composite approach creates a more specific diagnostic tool that leverages the combined information from multiple antigens, enabling better discrimination between active and latent TB while maintaining test feasibility.
2Reliability
If BCG vaccination is administered to prevent TB, then protection against severe forms of TB is provided, but cross-reactivity with TST and IGRA tests occurs, causing false positive results
Solution Approach 1:
The patent focuses on antigens with specific properties - selecting Rv3874c, Rv2681c, and Rv3615c based on their unique characteristics that differ from traditional BCG antigens. By targeting specific antigenic epitopes rather than using broad-spectrum mycobacterial antigens, the diagnostic test achieves local specificity that can distinguish BCG-vaccinated individuals from those with actual M. tuberculosis infection.
Solution Approach 2:
Instead of using traditional antigens that react with both BCG and M. tuberculosis (creating cross-reactivity), the patent inverts the approach by selecting antigens that are specific to M. tuberculosis and not expressed by BCG. This inversion of the traditional antigen selection strategy eliminates cross-reactivity while maintaining diagnostic sensitivity.
3Measurement precision
If new TB vaccines with multiple antigens are developed to improve diagnostic accuracy and vaccine efficacy, then discrimination between active and latent TB improves, but the complexity of vaccine composition and manufacturing increases
Solution Approach 1:
The patent selects antigens that serve multiple functions: Rv3874c, Rv2681c, and Rv3615c are chosen not only for their diagnostic value in discriminating active from latent TB but also for their potential as vaccine targets. This multi-functionality allows the same antigen combination to be used for both diagnostic testing and vaccine development, simplifying the overall implementation strategy despite the increased antigen complexity.
Solution Approach 2:
The patent modifies key parameters of the diagnostic and vaccine system by transitioning from single-antigen or traditional multi-antigen formulations to a specifically defined trio of antigens (Rv3874c, Rv2681c, Rv3615c) with optimized representations. This parameter change in antigen selection and formulation enables improved discrimination accuracy while establishing a standardized, reproducible manufacturing approach.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides new immunological compositions and vaccines comprising selected M. tuberculosis antigens and antigenic peptides as well as nucleic acids encoding said antigens for use in the prevention, prophylaxis and treatment of mycobacterial infection, especially tuberculosis. In particular the invention provides recombinant BCG based vaccines in which one or more of the selected M. tuberculosis antigens are over expressed. The invention further provides isolated peptides for use in methods for diagnosing, characterizing, or classifying mycobacterial infections.